Reduced Occupational Sitting in Type 2 Diabetes Using mHealth (Mobile Health)

Summary

Type 2 diabetes mellitus (T2DM) patients are suboptimal treated due to low uptake of physical activity. Recent research shows promising beneficial health effects from reducing sitting time by regular short bouts of light-intensity physical activity. These findings open up for a new focus in T2DM treatment but conclusive evidence is missing as studies have been short-term trials, mainly conducted in laboratory environments. Recent research suggest that reduced sitting and increased physical activity can be supported at a low cost by mHealth (mobile health) technology such as activity tracker armbands that warns of prolonged sitting and SMS text messages that reminds of activity breaks.

The overarching purpose of the project is to evaluate the effects of an intervention aimed to reduce occupational sitting in T2DM using mHealth (mobile health). It is hypothesized that the intervention will lead to (1) Activity changes - reduced sitting time and/or increased number of steps (primary outcome measures) and (2) Health effects - lower fatigue, improved health-related quality of life, reduced cardiometabolic risk, less sick leave, less medication, less musculoskeletal problems (secondary outcome measures)

Conditions

• Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

Patient-centered counselling and written material

Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.

BEHAVIORAL

mHealth

1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps. 2. SMS text messages; reminds of activity breaks. 3. Mobile video instruction for standing pause gymnastics.

Sponsors & Collaborators

• Norrbottens County Council

  collaborator OTHER_GOV

• Vastra Gotaland Region

  collaborator OTHER_GOV

• Region Östergötland

  collaborator OTHER

• Region Stockholm

  collaborator OTHER_GOV

• Region Örebro County

  collaborator OTHER

• Region Västerbotten

  collaborator OTHER_GOV

• Region Jämtland Härjedalen

  collaborator OTHER

• Umeå University

  lead OTHER

Principal Investigators

• Patrik Wennberg · Umeå University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

64 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-12-08

Primary Completion

2023-12-30

Completion

2024-12-30

Countries

• Sweden

Study Locations